BACKGROUND: The new 20 mg/mL hyaluronic acid (HA) dermal filler is a smooth, highly cohesive, viscous formulation developed to restore volume in aesthetic facial rejuvenation. OBJECTIVE Evaluate clinical experience with 20 mg/mL HA dermal filler to date and comment on its current and potential uses within the facial rejuvenation treatment paradigm. METHODS AND MATERIALS: In this paper, the authors review the unique physical and chemical properties of 20 mg/mL HA dermal filler as well as clinical experience with the product to date. RESULTS: Overall, the 20 mg/mL smooth, cohesive, viscous HA filler was especially effective in restoring volume in the malar region and chin. Volume loss resolved significantly in patients in clinical trials(1) and treatment effects were observed to be maintained from six to 18 months.(2) Physicians reported the agent was highly effective as well as easy to inject, sculpt and mold. The treatment was generally well tolerated and no instances of product migration from the injection site have been reported. Patient satisfaction was high, with the vast majority of trial participants acknowledging they would return for additional treatment and recommend the treatment to friends.(1,2) CONCLUSION: Initial experience shows the 20 mg/mL smooth, cohesive, viscous HA filler to be a useful addition to the facial rejuvenation armamentarium when used both alone and in combination with BTX-A.
BACKGROUND: The new 20 mg/mL hyaluronic acid (HA) dermal filler is a smooth, highly cohesive, viscous formulation developed to restore volume in aesthetic facial rejuvenation. OBJECTIVE Evaluate clinical experience with 20 mg/mL HA dermal filler to date and comment on its current and potential uses within the facial rejuvenation treatment paradigm. METHODS AND MATERIALS: In this paper, the authors review the unique physical and chemical properties of 20 mg/mL HA dermal filler as well as clinical experience with the product to date. RESULTS: Overall, the 20 mg/mL smooth, cohesive, viscous HA filler was especially effective in restoring volume in the malar region and chin. Volume loss resolved significantly in patients in clinical trials(1) and treatment effects were observed to be maintained from six to 18 months.(2) Physicians reported the agent was highly effective as well as easy to inject, sculpt and mold. The treatment was generally well tolerated and no instances of product migration from the injection site have been reported. Patient satisfaction was high, with the vast majority of trial participants acknowledging they would return for additional treatment and recommend the treatment to friends.(1,2) CONCLUSION: Initial experience shows the 20 mg/mL smooth, cohesive, viscous HA filler to be a useful addition to the facial rejuvenation armamentarium when used both alone and in combination with BTX-A.
Authors: Kenneth Beer; Joely Kaufman-Janette; David Bank; Brian Biesman; Steven Dayan; William Kim; Smita Chawla; Andrew Schumacher Journal: Dermatol Surg Date: 2021-01-01 Impact factor: 2.914